Press Releases

Endonovo Therapeutics Announces Partnership with Second Hospital

Download PDF

LOS ANGELES, CA , March 29, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced an agreement with a nationally recognized hospital group to enhance the quality of the healthcare/patient experience through the use of its electroceutical therapeutic device, SofPulse®. Endonovo has been approved to provide the hospital with an initial order of SofPulse® devices for use in the hospital and expects continued follow-on orders for additional SofPulse® units.

Alan Collier, Endonovo’s Chief Executive Officer, stated “We are excited to work with a second hospital group and continue to expand our ability to improve the patient postoperative experience. We are in discussions with several other hospital groups and medical facilities to bring the SofPulse® unique technology to the market in the near future. We anticipate this latest relationship will provide a better recovery and better outcomes for patients. We also believe this second hospital group further validates SofPulse® efficacy in wound healing and pain management through past and proven results. We continue to expand the SofPulse® network with our leadership team, partners and the collective desire to be out-in-front with value-based health care. Together, we’re transforming how people get the care they need.”

“With the opioid epidemic at its current levels, SofPulse® provides the alternative to postoperative pain management people are demanding today.” continued Mr. Collier.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact:

Endonovo Therapeutics, Inc. Mr. Andrew Barwicki


Source: Endonovo Therapeutics, Inc.